logo-loader

Avacta Plc's therapeutics business 'has huge amount of potential' - analyst Ed Stacey

Published: 23:30 09 Apr 2019 AEST

Capital Network analyst Ed Stacey discusses the major value driver for Avacta - the development of its proprietary Affimer technology for therapeutics, particularly in the immune-oncology (I-O) space.

The group's reported interim results to January 2019 today, revealing revenues of £1.0mln and illustrating good progress on its key development programmes.

Poseidon Nickel signs binding agreement with Mineral Resources to divest...

Departing Poseidon Nickel Ltd (ASX:POS, OTC:PSDNF) CEO Craig Jones and incoming CEO Brendan Shalders join Proactive’s Jonathan Jackson to discuss the divestment of Lake Johnston to Mineral Resources Ltd (ASX:MIN). Jones, who has played a pivotal role in this strategic move, shared insights on...

1 hour, 19 minutes ago